| Expression pattern: |
UP |
| Associated gene: |
HBx, METTL3, YTHDC1, ARL3, WNT2, UBE2T, MDM2, TGF-beta2, POLR3G, Ki-67 |
| Associated microRNA: |
miR-1305 |
| Biological function: |
circ-ARL3 promotes proliferation, invasion and in vivo growth of HBV-positive HCC cells; knockdown inhibits proliferation and invasion and retards tumor growth. |
| Molecular mechanism: |
HBx upregulates METTL3, increasing m6A modification of circ-ARL3; YTHDC1 binds m6A-modified circ-ARL3 and promotes its reverse splicing and biogenesis; cytoplasmic circ-ARL3 sponges miR-1305 to relieve repression of oncogenic targets including WNT2, UBE2T, MDM2, TGF-beta2 and POLR3G. |
| Biological pathway or process: |
proliferation (promotes); invasion (promotes); ceRNA regulation (promotes); m6A modification (other); mRNA stability (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; FISH / smFISH; MeRIP / MeRIP-seq; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; RNA Pull-Down; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; In Vivo Animal Model; Western Blot; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circ-ARL3 was positively correlated with malignant clinical features and poor prognosis; circ-ARL3 expression was positively associated with HBsAg+, larger tumor volume and advanced clinical stage, and high expression predicted shorter survival time. |
| Description: |
circ-ARL3 is an HBV-related, up-regulated circRNA in HBV-positive HCC, and high expression is associated with malignant clinical features and poor survival. Mechanistically, HBx-induced METTL3/YTHDC1-dependent m6A regulation increases circ-ARL3 biogenesis, and cytoplasmic circ-ARL3 promotes HCC proliferation, invasion and xenograft growth by sponging miR-1305 and derepressing oncogenic target genes. |
| Confidence score: |
0.8609 |